insights_auto
Why is ABUS up 2.07%?
Dive Deeperchevron_right
ABUS:NASDAQ
Arbutus Biopharma Corp
$4.20
arrow_upward
+2.07%(+0.085) 1D
Oct 14, 9:55:05 AM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ABUS...
Open
$4.07
High
$4.20
Low
$4.05
Mkt. cap
831.05M
Avg. vol.
6.78M
Volume
68.00K
P/E ratio
5.36
52-wk high
$5.45
52-wk low
$3.50
EPS
$0.78
Beta
0.76
Shares outstanding
198.11M
No. of employees
19
Open
$4.07
High
$4.20
Low
$4.05
Mkt. cap
831.05M
Avg. vol.
6.78M
Volume
68.00K
P/E ratio
5.36
52-wk high
$5.45
52-wk low
$3.50
EPS
$0.78
Beta
0.76
Shares outstanding
198.11M
No. of employees
19
News stories
From web sources and news partners
PR Newswire UK
·
1 hour ago
Oracle NetSuite Announces Launch of AI-first QuickStart: NYSE Content Update
Central Oregon Daily
·
38 minutes ago
Wall St set for lower open as hot inflation data fuels rate-hike bets
Reuters
·
20 minutes ago
Wall St opens lower after hot CPI data fuels rate-hike bets
24/7 Wall St.
·
2 hours ago
Jim Cramer Says Most of the Market Is Already in a Bear Market Despite S&P 500 Rally
Profile
Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
It is headquartered in Warminster, Pennsylvania. The company was formerly known as Tekmira, which was spun out of Inex Pharmaceuticals in 2007. Wikipedia
About Arbutus Biopharma Corp
CEOWilliam H. Collier
Employees19
Founded2007
HeadquartersWarminster Township, Pennsylvania, United States
SectorBiotechnology
Websitearbutusbio.com